Ignite Creation Date:
2024-05-06 @ 9:50 AM
Last Modification Date:
2024-10-26 @ 12:20 PM
Study NCT ID:
NCT03083665
Status:
COMPLETED
Last Update Posted:
2024-06-11
First Post:
2017-02-28
Brief Title:
A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants 16 to 80 Years of Age With Epilepsy
Sponsor:
UCB Biopharma SRL
Organization:
UCB Pharma
Study Overview
Official Title:
A Randomized Double-blind Placebo-controlled Multicenter Parallel-group Study to Evaluate the Efficacy and Safety of Adjunctive Brivaracetam in Subjects 16 to 80 Years of Age With Partial Seizures With or Without Secondary Generalization
Status:
COMPLETED
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to evaluate the efficacy of brivaracetam BRV compared to placebo PBO as adjunctive treatment in subjects 16 to 80 years of age with partial seizures with or without secondary generalization despite current treatment with 1 or 2 concomitant antiepileptic drugs AEDs and to assess the safety and tolerability of BRV in subjects 16 years to 80 years of age
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None